Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Share-based Compensation: 2019-2025

Historic Share-based Compensation for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $1.1 million.

  • Eton Pharmaceuticals' Share-based Compensation fell 54.18% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 7.84%. This contributed to the annual value of $3.2 million for FY2024, which is 0.89% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Share-based Compensation stood at $1.1 million for Q3 2025, which was down 47.90% from $2.1 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Share-based Compensation high stood at $2.4 million for Q3 2023, and its period low was $673,000 during Q1 2021.
  • In the last 3 years, Eton Pharmaceuticals' Share-based Compensation had a median value of $872,000 in 2023 and averaged $1.3 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first spiked by 151.53% in 2023, then plummeted by 54.18% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Share-based Compensation (Quarterly) stood at $863,000 in 2021, then rose by 2.67% to $886,000 in 2022, then declined by 15.35% to $750,000 in 2023, then grew by 4.27% to $782,000 in 2024, then slumped by 54.18% to $1.1 million in 2025.
  • Its Share-based Compensation stands at $1.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $1.2 million for Q1 2025.